4,599 Shares of Kymera Therapeutics, Inc. $KYMR Acquired by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. acquired a new position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) during the 3rd quarter, Holdings Channel.com reports. The institutional investor acquired 4,599 shares of the company’s stock, valued at approximately $514,000.

A number of other large investors have also recently made changes to their positions in the stock. China Universal Asset Management Co. Ltd. increased its holdings in Kymera Therapeutics by 20.8% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 15,812 shares of the company’s stock worth $1,747,000 after acquiring an additional 2,721 shares in the last quarter. Sterling Capital Management LLC lifted its holdings in Kymera Therapeutics by 378.6% during the third quarter. Sterling Capital Management LLC now owns 1,919 shares of the company’s stock valued at $215,000 after purchasing an additional 1,518 shares in the last quarter. Inspire Investing LLC purchased a new position in Kymera Therapeutics during the third quarter valued at approximately $482,000. Nisa Investment Advisors LLC lifted its holdings in Kymera Therapeutics by 45.9% during the third quarter. Nisa Investment Advisors LLC now owns 2,073 shares of the company’s stock valued at $232,000 after purchasing an additional 652 shares in the last quarter. Finally, Abel Hall LLC boosted its position in shares of Kymera Therapeutics by 4.0% in the third quarter. Abel Hall LLC now owns 4,870 shares of the company’s stock worth $544,000 after purchasing an additional 189 shares during the period.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on KYMR shares. TD Cowen raised shares of Kymera Therapeutics to a “strong-buy” rating in a research note on Monday, August 24th. Citigroup upped their target price on shares of Kymera Therapeutics from $135.00 to $150.00 and gave the stock a “buy” rating in a report on Monday, October 5th. Wells Fargo & Company increased their price target on Kymera Therapeutics from $116.00 to $151.00 and gave the stock an “overweight” rating in a research note on Thursday, August 27th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kymera Therapeutics in a research note on Thursday, October 15th. Finally, Royal Bank Of Canada boosted their price objective on Kymera Therapeutics from $112.00 to $116.00 and gave the company a “sector perform” rating in a research report on Friday, October 30th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Kymera Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $139.16.

Insider Transactions at Kymera Therapeutics

In related news, CEO Nello Mainolfi sold 30,000 shares of the business’s stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $113.80, for a total value of $3,414,000.00. Following the sale, the chief executive officer directly owned 666,568 shares in the company, valued at approximately $75,855,438.40. The trade was a 4.31% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Brian Adams sold 6,371 shares of the stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $116.83, for a total value of $744,323.93. Following the transaction, the insider directly owned 50,254 shares of the company’s stock, valued at approximately $5,871,174.82. The trade was a 11.25% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 15.98% of the company’s stock.

Kymera Therapeutics Stock Performance

KYMR opened at $138.86 on Tuesday. The stock has a market capitalization of $11.85 billion, a price-to-earnings ratio of -38.36 and a beta of 2.04. The company has a fifty day moving average of $116.09 and a 200 day moving average of $98.15. Kymera Therapeutics, Inc. has a fifty-two week low of $58.87 and a fifty-two week high of $140.67.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings results on Thursday, October 29th. The company reported ($1.32) EPS for the quarter, missing the consensus estimate of ($1.26) by ($0.06). Kymera Therapeutics had a negative return on equity of 22.39% and a negative net margin of 285.33%. The company had revenue of $1.35 million during the quarter, compared to analysts’ expectations of $3.28 million. During the same quarter in the previous year, the firm earned ($0.94) EPS. The firm’s revenue for the quarter was up .0% compared to the same quarter last year. On average, equities research analysts forecast that Kymera Therapeutics, Inc. will post -3.88 earnings per share for the current year.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical-stage biotechnology company developing medicines that selectively remove disease-causing proteins from cells. Its approach, known as targeted protein degradation, uses the body’s natural protein-disposal system and is designed to address targets that may be difficult to reach with conventional drugs.

The company’s research and development programs include small-molecule protein degraders for conditions involving immune and inflammatory pathways, as well as cancer.